Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.Qiu Li, Chunlei Jin, Shukui Qin et al.|Journal of Clinical Oncology|2020Cited by 36
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)Yu Chi Yang, Jun Zhou, Shusen Zheng et al.|Liver Cancer|2022Cited by 22